<p>Quince Therapeutics（纳斯达克股票代码：QNCX - 获取免费报告）在周一向客户和投资者发布的研究报告中，D. Boral Capital 将其目标价格从 4.00 美元上调至 5.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。D. Boral Capital 的目标价格暗示该股票当前价格有 29.70% 的潜在上涨空间。</p>
<p>获取 <strong>Quince Therapeutics</strong> 的提醒：</p>
<p>其他一些股票研究分析师最近也对该公司发布了报告。Weiss Ratings 在 12 月 8 日的研究报告中重申了对 Quince Therapeutics 股票的 “卖出（e+）” 评级。Zacks Research 在 8 月 26 日的研究报告中将 Quince Therapeutics 的评级从 “强烈卖出” 上调至 “持有”。一位股票研究分析师给予该股票 “强烈买入” 评级，五位分析师给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Quince Therapeutics 的共识评级为 “适度买入”，共识目标价格为 8.20 美元。</p>
<p><strong>阅读我们关于 Quince Therapeutics 的最新报告</strong></p>
<h2>Quince Therapeutics 价格表现</h2>
<p>周一，QNCX 股票在交易中下跌 0.37 美元，达到 3.86 美元。该公司的交易量为 955,662 股，而其平均交易量为 333,276 股。Quince Therapeutics 的年内最低价为 0.72 美元，年内最高价为 4.55 美元。该公司的 50 日简单移动平均线为 2.34 美元，200 日简单移动平均线为 1.84 美元。公司的市值为 2.1465 亿美元，市盈率为-3.19，贝塔值为 1.02。</p>
<p>Quince Therapeutics（纳斯达克股票代码：QNCX - 获取免费报告）最后一次发布季度财报是在 11 月 12 日。该公司报告本季度每股收益为（0.25 美元），低于分析师的共识预期（0.20 美元）0.05 美元。分析师预测 Quince Therapeutics 在本年度的每股收益将为-1.21 美元。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金最近增加或减少了对该公司的持股。Nantahala Capital Management LLC 在第三季度将其在 Quince Therapeutics 的持股增加了 21.6%。Nantahala Capital Management LLC 现在拥有 3073729 股该公司的股票，价值 500 万美元，在此期间又购买了 545427 股。Vanguard Group Inc.在第三季度将其在 Quince Therapeutics 的持股增加了 21.3%。Vanguard Group Inc.现在拥有 1763387 股该公司的股票，价值 287.4 万美元，在上个季度又购买了 309349 股。Millennium Management LLC 在第三季度将其在 Quince Therapeutics 的持股增加了 1152.9%。Millennium Management LLC 现在拥有 1386776 股该公司的股票，价值 226 万美元，在此期间又购买了 1276094 股。Ieq Capital LLC 在第一季度购买了 Quince Therapeutics 的新股份，价值 107.3 万美元。最后，ADAR1 Capital Management LLC 在第三季度将其在 Quince Therapeutics 的持股增加了 442.1%。ADAR1 Capital Management LLC 现在拥有 775034 股该公司的股票，价值 126.3 万美元，在上个季度又购买了 632076 股。30.75% 的股票由机构投资者持有。</p>
<h2>关于 Quince Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Quince Therapeutics, Inc 是一家生物制药公司，专注于为患有严重和罕见疾病的患者获取、开发和商业化治疗方案。该公司的主要资产候选药物包括 EryDex，用于治疗罕见的儿童神经退行性疾病，包括 A-T，这是一种由 ATM 基因突变引起的遗传性常染色体隐性神经退行性疾病和免疫缺陷疾病。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Quince Therapeutics</li>
<li>什么是 MACD 指标，如何在交易中使用它</li>
<li>内部人士购买天然气股票：2 只值得关注的股票</li>
<li>什么是 S&amp;P/TSX 指数？</li>
<li>Rivian 的自主驾驶重磅消息改变了一切——甚至是其估值</li>
<li>投资者需要知道的以战胜市场的信息</li>
<li>金融行业在资本轮换和领导权转移中突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UU5DWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UU5DWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Quince Therapeutics 吗？</h2>
<p>在考虑 Quince Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Quince Therapeutics 并不在名单上。</p>
<p>虽然 Quince Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

QNCX

<p>D. Boral Capital 将 Quince Therapeutics 的目标股价从 4.00 美元上调至 5.00 美元，维持 “买入” 评级，暗示潜在上涨幅度为 29.70%。Quince 的共识评级为 “适度买入”，目标股价为 8.20 美元。该股票交易价格为 3.86 美元，市值为 2.1465 亿美元。机构投资者增加了持股，其中 Nantahala Capital 和 Vanguard Group 的增持尤为显著。Quince 专注于罕见疾病的治疗，EryDex 是其在神经退行性疾病领域的主要资产</p>

<p>Quince Therapeutics (NASDAQ:QNCX - Get Free Report) had its price target lifted by equities research analysts at D. Boral Capital from $4.00 to $5.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. D. Boral Capital's price target suggests a potential upside of 29.70% from the stock's current price.</p>
<div class="lb-trans"><p>Quince Therapeutics（纳斯达克股票代码：QNCX - 获取免费报告）在周一向客户和投资者发布的研究报告中，D. Boral Capital 将其目标价格从 4.00 美元上调至 5.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。D. Boral Capital 的目标价格暗示该股票当前价格有 29.70% 的潜在上涨空间。</p>
</div><p>Get <strong>Quince Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Quince Therapeutics</strong> 的提醒：</p>
</div><p>A number of other equities research analysts also recently issued reports on the company. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Quince Therapeutics in a research report on Monday, December 8th. Zacks Research raised shares of Quince Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Quince Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $8.20.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对该公司发布了报告。Weiss Ratings 在 12 月 8 日的研究报告中重申了对 Quince Therapeutics 股票的 “卖出（e+）” 评级。Zacks Research 在 8 月 26 日的研究报告中将 Quince Therapeutics 的评级从 “强烈卖出” 上调至 “持有”。一位股票研究分析师给予该股票 “强烈买入” 评级，五位分析师给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Quince Therapeutics 的共识评级为 “适度买入”，共识目标价格为 8.20 美元。</p>
</div><p><strong>Read Our Latest Report on Quince Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Quince Therapeutics 的最新报告</strong></p>
</div><h2>Quince Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Quince Therapeutics 价格表现</h2>
</div><p>Shares of QNCX stock traded down $0.37 during trading on Monday, reaching $3.86. The company had a trading volume of 955,662 shares, compared to its average volume of 333,276. Quince Therapeutics has a one year low of $0.72 and a one year high of $4.55. The firm's 50 day simple moving average is $2.34 and its two-hundred day simple moving average is $1.84. The company has a market capitalization of $214.65 million, a PE ratio of -3.19 and a beta of 1.02.</p>
<div class="lb-trans"><p>周一，QNCX 股票在交易中下跌 0.37 美元，达到 3.86 美元。该公司的交易量为 955,662 股，而其平均交易量为 333,276 股。Quince Therapeutics 的年内最低价为 0.72 美元，年内最高价为 4.55 美元。该公司的 50 日简单移动平均线为 2.34 美元，200 日简单移动平均线为 1.84 美元。公司的市值为 2.1465 亿美元，市盈率为-3.19，贝塔值为 1.02。</p>
</div><p>Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). Analysts forecast that Quince Therapeutics will post -1.21 earnings per share for the current year.</p>
<div class="lb-trans"><p>Quince Therapeutics（纳斯达克股票代码：QNCX - 获取免费报告）最后一次发布季度财报是在 11 月 12 日。该公司报告本季度每股收益为（0.25 美元），低于分析师的共识预期（0.20 美元）0.05 美元。分析师预测 Quince Therapeutics 在本年度的每股收益将为-1.21 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC raised its stake in Quince Therapeutics by 21.6% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,073,729 shares of the company's stock worth $5,010,000 after buying an additional 545,427 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Quince Therapeutics by 21.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company's stock worth $2,874,000 after purchasing an additional 309,349 shares in the last quarter. Millennium Management LLC grew its position in Quince Therapeutics by 1,152.9% in the 3rd quarter. Millennium Management LLC now owns 1,386,776 shares of the company's stock valued at $2,260,000 after purchasing an additional 1,276,094 shares during the period. Ieq Capital LLC bought a new stake in Quince Therapeutics during the 1st quarter valued at $1,073,000. Finally, ADAR1 Capital Management LLC raised its holdings in Quince Therapeutics by 442.1% during the third quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company's stock worth $1,263,000 after buying an additional 632,076 shares during the last quarter. 30.75% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近增加或减少了对该公司的持股。Nantahala Capital Management LLC 在第三季度将其在 Quince Therapeutics 的持股增加了 21.6%。Nantahala Capital Management LLC 现在拥有 3073729 股该公司的股票，价值 500 万美元，在此期间又购买了 545427 股。Vanguard Group Inc.在第三季度将其在 Quince Therapeutics 的持股增加了 21.3%。Vanguard Group Inc.现在拥有 1763387 股该公司的股票，价值 287.4 万美元，在上个季度又购买了 309349 股。Millennium Management LLC 在第三季度将其在 Quince Therapeutics 的持股增加了 1152.9%。Millennium Management LLC 现在拥有 1386776 股该公司的股票，价值 226 万美元，在此期间又购买了 1276094 股。Ieq Capital LLC 在第一季度购买了 Quince Therapeutics 的新股份，价值 107.3 万美元。最后，ADAR1 Capital Management LLC 在第三季度将其在 Quince Therapeutics 的持股增加了 442.1%。ADAR1 Capital Management LLC 现在拥有 775034 股该公司的股票，价值 126.3 万美元，在上个季度又购买了 632076 股。30.75% 的股票由机构投资者持有。</p>
</div><h2>About Quince Therapeutics</h2>
<div class="lb-trans"><h2>关于 Quince Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.</p>
<div class="lb-trans"><p>Quince Therapeutics, Inc 是一家生物制药公司，专注于为患有严重和罕见疾病的患者获取、开发和商业化治疗方案。该公司的主要资产候选药物包括 EryDex，用于治疗罕见的儿童神经退行性疾病，包括 A-T，这是一种由 ATM 基因突变引起的遗传性常染色体隐性神经退行性疾病和免疫缺陷疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Quince Therapeutics</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Insiders Buy Natural Gas Stocks: 2 for the Watchlist</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>Rivian’s Autonomy Bombshell Changes Everything—Even Its Valuation</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>Financial Sector Breaks Out as Capital Rotates and Leadership Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Quince Therapeutics</li>
<li>什么是 MACD 指标，如何在交易中使用它</li>
<li>内部人士购买天然气股票：2 只值得关注的股票</li>
<li>什么是 S&amp;P/TSX 指数？</li>
<li>Rivian 的自主驾驶重磅消息改变了一切——甚至是其估值</li>
<li>投资者需要知道的以战胜市场的信息</li>
<li>金融行业在资本轮换和领导权转移中突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UU5DWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=QNCX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Quince Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Quince Therapeutics 吗？</h2>
</div><p>Before you consider Quince Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Quince Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quince Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Quince Therapeutics 并不在名单上。</p>
</div><p>While Quince Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Quince Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Quince Therapeutics（纳斯达克股票代码：QNCX）的目标价在 D. Boral Capital 被上调至 5.00 美元